TSE:2802Food
Ajinomoto (TSE:2802) Is Up 12.0% After EPS Beat And Bio-Pharma Push - Has The Bull Case Changed?
Ajinomoto Co., Inc. recently reported full-year results for the period ended March 31, 2026, with sales of ¥1,583,719 million and net income of ¥134,675 million, while also sharing its biopharma capabilities at the 22nd Annual PEGS Boston Summit through a presentation by Yumi Nagase.
The sharp improvement in earnings per share, alongside Ajinomoto’s emphasis on bio-pharma and functional materials at an industry conference, highlights how its higher-value healthcare and technology-oriented...